{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:00:21Z","timestamp":1792699221631,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40265-023-01931-3","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T09:29:09Z","timestamp":1692782949000},"page":"1255-1267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Pyoderma Gangrenosum: Treatment Options"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3893-328X","authenticated-orcid":false,"given":"Joachim","family":"Dissemond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"issue":"2","key":"1931_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2019.08.001","volume":"83","author":"A Xu","year":"2020","unstructured":"Xu A, Balgobind A, Strunk A, Garg A, Alloo A. Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis. J Am Acad Dermatol. 2020;83(2):425\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1931_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/wrr.13005","volume":"30","author":"VE Orfaly","year":"2022","unstructured":"Orfaly VE, Reese AM, Friedman M, Latour E, Ortega-Loayza AG. Pyoderma gangrenosum study pilot registry: the first step to a better understanding. Wound Repair Regen. 2022;30(3):334\u20137.","journal-title":"Wound Repair Regen"},{"issue":"9","key":"1931_CR3","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/jid.2012.130","volume":"132","author":"SM Langan","year":"2012","unstructured":"Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132(9):2166\u201370.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1931_CR4","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","volume":"165","author":"AM Binus","year":"2011","unstructured":"Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011;165(6):1244\u201350.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1931_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00005792-200001000-00004","volume":"79","author":"ML Bennett","year":"2000","unstructured":"Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine. 2000;79(1):37\u201346.","journal-title":"Medicine"},{"issue":"1","key":"1931_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","volume":"6","author":"E Maverakis","year":"2020","unstructured":"Maverakis E, Marzano AV, Le ST, Callen JP, Br\u00fcggen MC, Guenova E, Dissemond J, Shinkai K, Langan SM. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020;6(1):81.","journal-title":"Nat Rev Dis Primers"},{"key":"1931_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.639404","volume":"8","author":"T Ergun","year":"2021","unstructured":"Ergun T. Pathergy phenomenon. Front Med. 2021;8: 639404.","journal-title":"Front Med"},{"issue":"18","key":"1931_CR8","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa013383","volume":"347","author":"RH Weenig","year":"2002","unstructured":"Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med. 2002;347(18):1412\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"1931_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jid.2020.04.019","volume":"141","author":"C Haag","year":"2021","unstructured":"Haag C, Hansen T, Hajar T, Latour E, Keller J, Shinkai K, Ortega-Loayza AG. Comparison of three diagnostic frameworks for pyoderma gangrenosum. J Invest Dermatol. 2021;141(1):59\u201363.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1931_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/bjd.20967","volume":"186","author":"MS Min","year":"2022","unstructured":"Min MS, Kus K, Wei N, Kassamali B, Faletsky A, Mostaghimi A, Lebwohl MG. Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study. Br J Dermatol. 2022;186(6):1035\u20137.","journal-title":"Br J Dermatol"},{"key":"1931_CR11","first-page":"196","volume-title":"Weedon's skin pathology","author":"D Weedon","year":"2010","unstructured":"Weedon D. The vasculopathic reaction pattern. In: Weedon D, editor. Weedon\u2019s skin pathology. 3rd ed. London: Churchill Livingstone; 2010. p. 196\u2013244.","edition":"3"},{"issue":"4","key":"1931_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40257-018-0356-7","volume":"19","author":"K Kridin","year":"2018","unstructured":"Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(4):479\u201387.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1931_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10067-020-05253-7","volume":"40","author":"K Kridin","year":"2021","unstructured":"Kridin K, Damiani G, Cohen AD. Rheumatoid arthritis and pyoderma gangrenosum: a population-based case-control study. Clin Rheumatol. 2021;40(2):521\u20138.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"1931_CR14","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1007\/s10067-021-05768-7","volume":"40","author":"E Sawka","year":"2021","unstructured":"Sawka E, Zhou A, Latour E, Friedman M, Ortega-Loayza AG. Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review. Clin Rheumatol. 2021;40(10):3963\u20139.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"1931_CR15","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jaad.2019.09.032","volume":"82","author":"CM Montagnon","year":"2020","unstructured":"Montagnon CM, Fracica EA, Patel AA, Camilleri MJ, Murad MH, Dingli D, Wetter DA, Tolkachjov SN. Pyoderma gangrenosum in hematologic malignancies: a systematic review. J Am Acad Dermatol. 2020;82(6):1346\u201359.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1931_CR16","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s00277-019-03732-9","volume":"98","author":"AS Gupta","year":"2019","unstructured":"Gupta AS, Ortega-Loayza AG. Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. Ann Hematol. 2019;98(9):2247\u20138.","journal-title":"Ann Hematol"},{"issue":"1","key":"1931_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jaad.2021.07.032","volume":"87","author":"M Ravi","year":"2022","unstructured":"Ravi M, Trinidad J, Spaccarelli N, Kaffenberger B. The impact of comorbidity identification on outcomes in patients with pyoderma gangrenosum: a retrospective cohort study of previously hospitalized patients. J Am Acad Dermatol. 2022;87(1):194\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1931_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bjd.15193","volume":"177","author":"BC Wu","year":"2017","unstructured":"Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol. 2017;177(1):72\u201383.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1931_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40257-017-0308-7","volume":"19","author":"JY Wang","year":"2018","unstructured":"Wang JY, French LE, Shear NH, Amiri A, Alavi A. Drug-induced pyoderma gangrenosum: a review. Am J Clin Dermatol. 2018;19(1):67\u201377.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1931_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/vaccines10010087","volume":"10","author":"M Barry","year":"2022","unstructured":"Barry M, AlRajhi A, Aljerian K. Pyoderma gangrenosum induced by BNT162b2 COVID-19 vaccine in a healthy adult. Vaccines. 2022;10(1):87.","journal-title":"Vaccines"},{"issue":"2","key":"1931_CR21","doi-asserted-by":"publisher","first-page":"13221","DOI":"10.1111\/dth.13221","volume":"33","author":"P Aggarwal","year":"2020","unstructured":"Aggarwal P. Pyoderma gangrenosum adverse event with rituximab use: a postmarketing pharmacovigilance analysis. Dermatol Ther. 2020;33(2):13221.","journal-title":"Dermatol Ther"},{"issue":"12","key":"1931_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/jdv.18389","volume":"36","author":"J Franceschi","year":"2022","unstructured":"Franceschi J, Darrigade AS, Sanchez-Pena P, Legrain-Lifermann V, Milpied B. Pyoderma gangrenosum after mRNA-based SARS-CoV-2 vaccine. J Eur Acad Dermatol Venereol. 2022;36(12):969\u201370.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1931_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/jdv.17744","volume":"36","author":"T Gambichler","year":"2022","unstructured":"Gambichler T, Boms S, Susok L, Dickel H, Finis C, Abu Rached N, Barras M, St\u00fccker M, Kasakovski D. Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol. 2022;36(2):172\u201380.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1931_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/1097-0142(19910715)68:2<441::AID-CNCR2820680239>3.0.CO;2-4","volume":"68","author":"HJ Ross","year":"1991","unstructured":"Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer. 1991;68(2):441\u20133.","journal-title":"Cancer"},{"issue":"3","key":"1931_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2169\/internalmedicine.37.316","volume":"37","author":"S Takagi","year":"1998","unstructured":"Takagi S, Ohsaka A, Taguchi H, Kusama H, Matsuoka T. Pyoderma gangrenosum following cytosine arabinoside, aclarubicin and granulocyte colony-stimulating factor combination therapy in myelodysplastic syndrome. Intern Med. 1998;37(3):316\u20139.","journal-title":"Intern Med"},{"issue":"1","key":"1931_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CAD.0000000000001140","volume":"33","author":"N Khoshnam-Rad","year":"2022","unstructured":"Khoshnam-Rad N, Gheymati A, Jahangard-Rafsanjani Z. Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports. Anticancer Drugs. 2022;33(1):1\u20138.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"1931_CR27","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jaad.2015.11.040","volume":"74","author":"HS Jeong","year":"2016","unstructured":"Jeong HS, Layher H, Cao L, Vandergriff T, Dominguez AR. Pyoderma gangrenosum (PG) associated with levamisole-adulterated cocaine: clinical, serologic, and histopathologic findings in a cohort of patients. J Am Acad Dermatol. 2016;74(5):892\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1931_CR28","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","volume":"86","author":"MJ Murphy","year":"2022","unstructured":"Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022;86(5):1080\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"1931_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fphar.2019.00282","volume":"10","author":"S Garcovich","year":"2019","unstructured":"Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019;10:282.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1931_CR30","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/14712598.2022.2153593","volume":"22","author":"E Camela","year":"2022","unstructured":"Camela E, Potestio L, Fabbrocini G, Megna M. Paradoxical reactions to biologicals for psoriasis. Expert Opin Biol Ther. 2022;22(12):1435\u20137.","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"1931_CR31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/01.ASW.0000820252.96869.8e","volume":"35","author":"Y Lytvyn","year":"2022","unstructured":"Lytvyn Y, Mufti A, Maliyar K, Sachdeva M, Yeung J. Onset of pyoderma gangrenosum in patients on biologic therapies: a systematic review. Adv Skin Wound Care. 2022;35(8):454\u201360.","journal-title":"Adv Skin Wound Care"},{"issue":"4","key":"1931_CR32","doi-asserted-by":"publisher","first-page":"968","DOI":"10.4161\/hv.27699","volume":"10","author":"M Sobieszcza\u0144ska","year":"2014","unstructured":"Sobieszcza\u0144ska M, Tubek S, Kura I. Pyoderma gangrenosum-like skin changes after subcutaneous administration of low molecular weight heparin. Hum Vaccin Immunother. 2014;10(4):968\u20139.","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"1931_CR33","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/ndt\/12.7.1506","volume":"12","author":"CW Park","year":"1997","unstructured":"Park CW, Shin YS, Shin MJ, Koh SH, Chang KU, Ahn YB, Chang YS, Bang BK. Pyoderma gangrenosum and spinal epidural abscess after subcutaneous administration of recombinant human erythropoietin. Nephrol Dial Transplant. 1997;12(7):1506\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1931_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3747\/co.25.3779","volume":"25","author":"C Roy","year":"2018","unstructured":"Roy C, Adam JP, Morin F, Lemieux-Blanchard \u00c9, Doucet S, Friedmann D, Belisle A, Charpentier D. Azacitidine-induced pyoderma gangrenosum at injection sites in a patient with myelodysplastic syndrome. Curr Oncol. 2018;25(1):103\u20135.","journal-title":"Curr Oncol"},{"issue":"4","key":"1931_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/bjh.13341","volume":"169","author":"E Tseng","year":"2015","unstructured":"Tseng E, Alhusayen R, Sade S, Buckstein R, Prica A. Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome. Br J Haematol. 2015;169(4):461.","journal-title":"Br J Haematol"},{"issue":"1","key":"1931_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14740338.2018.1396316","volume":"17","author":"SR Feldman","year":"2018","unstructured":"Feldman SR, Lacy FA, Huang WW. The safety of treatments used in pyoderma gangrenosum. Expert Opin Drug Saf. 2018;17(1):55\u201361.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1931_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/095466301750163518","volume":"12","author":"CC Lyon","year":"2001","unstructured":"Lyon CC, Stapleton M, Smith AJ, Mendelsohn S, Beck MH, Griffiths CE. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatolog Treat. 2001;12(1):13\u20137.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1931_CR38","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaad.2016.06.016","volume":"75","author":"KS Thomas","year":"2016","unstructured":"Thomas KS, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell E, Mason JM, Johnston GA, Wahie S, Williams HC. UK Dermatology Clinical Trials Network\u2019s STOP GAP Team. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. J Am Acad Dermatol. 2016;75(5):940\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1931_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00004836-198512000-00011","volume":"7","author":"F Goldstein","year":"1985","unstructured":"Goldstein F, Krain R, Thornton JJ. Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol. 1985;7(6):499\u2013501.","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"1931_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0190-9622(83)70172-6","volume":"9","author":"JL Jennings","year":"1983","unstructured":"Jennings JL. Pyoderma gangrenosum: successful treatment with intralesional steroids. J Am Acad Dermatol. 1983;9(4):575\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1931_CR41","first-page":"151","volume":"31","author":"D Baltazar","year":"2019","unstructured":"Baltazar D, Haag C, Gupta AS, Marzano AM, Ortega Loayza AG. A comprehensive review of local pharmacologic therapy for pyoderma gangrenosum. Wounds. 2019;31(6):151\u20137.","journal-title":"Wounds"},{"key":"1931_CR42","first-page":"20162","volume":"2017","author":"C Moreira","year":"2017","unstructured":"Moreira C, Lopes S, Cruz MJ, Azevedo F. Topical timolol for the treatment of pyoderma gangrenosum. BMJ Case Rep. 2017;2017:20162.","journal-title":"BMJ Case Rep"},{"issue":"10","key":"1931_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164080","volume":"11","author":"AK Alves de Medeiros","year":"2016","unstructured":"Alves de Medeiros AK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS ONE. 2016;11(10): 164080.","journal-title":"PLoS ONE"},{"issue":"2","key":"1931_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdv.16034","volume":"34","author":"VR Barton","year":"2020","unstructured":"Barton VR, Le ST, Wang JZ, Toussi A, Sood A, Maverakis E. Peristomal ulcers misdiagnosed as pyoderma gangrenosum: a common error. J Eur Acad Dermatol Venereol. 2020;34(2):108\u201310.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1931_CR45","first-page":"815","volume":"19","author":"J Dissemond","year":"2021","unstructured":"Dissemond J, Assenheimer B, Gerber V, Hintner M, Puntigam MJ, Kolbig N, Koller S, Kurz P, L\u00e4uchli S, Probst S, Protz K, Steiniger A, Strohal R, Traber J, Kottner J. Moisture-associated skin damage (MASD): a best practice recommendation from Wund-D.A.CH. J Dtsch Dermatol Ges. 2021;19(6):815\u201325.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"1931_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2230.2009.03413.x","volume":"35","author":"M Chriba","year":"2010","unstructured":"Chriba M, Skellett AM, Levell NJ. Beclometasone inhaler used to treat pyoderma gangrenosum. Clin Exp Dermatol. 2010;35(3):337\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1931_CR47","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/bjd\/ljad006","volume":"188","author":"T Swift","year":"2023","unstructured":"Swift T. Peristomal skin complications: new materials needed to ease the ostomy care market. Br J Dermatol. 2023;188(4):455\u20136.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1931_CR48","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/iwj.13164","volume":"16","author":"WA Pearson","year":"2019","unstructured":"Pearson WA, Prentice DA, Sinclair DL, Lim LY, Carville KJ. A novel topical therapy for resistant and early peristomal pyoderma gangrenosum. Int Wound J. 2019;16(5):1136\u201343.","journal-title":"Int Wound J"},{"issue":"5","key":"1931_CR49","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","volume":"23","author":"CA Maronese","year":"2022","unstructured":"Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG, Marzano AV. Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol. 2022;23(5):615\u201334.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1931_CR50","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/bjd.14619","volume":"175","author":"K Herberger","year":"2016","unstructured":"Herberger K, Dissemond J, Hohaus K, Schaller J, Anastasiadou Z, Augustin M. Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients. Br J Dermatol. 2016;175(5):1070\u20132.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1931_CR51","doi-asserted-by":"publisher","first-page":"119","DOI":"10.12788\/cutis.0076","volume":"106","author":"L Afifi","year":"2020","unstructured":"Afifi L, Ortega-Loayza AG, Shinkai K. Management of classic ulcerative pyoderma gangrenosum. Cutis. 2020;106(3):119\u201323.","journal-title":"Cutis"},{"key":"1931_CR52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2741\/1249","volume":"9","author":"NR Barshes","year":"2004","unstructured":"Barshes NR, Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci. 2004;9:411\u201320.","journal-title":"Front Biosci"},{"issue":"4","key":"1931_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000481432","volume":"233","author":"AGA Kolios","year":"2017","unstructured":"Kolios AGA, G\u00fcbeli A, Meier B, Maul JT, K\u00fcndig T, Nilsson J, Hafner J, Guenova E, Kerl K, Anliker M, Kempf W, Navarini AA, French LE, Cozzio A. Clinical disease patterns in a regional swiss cohort of 34 pyoderma gangrenosum patients. Dermatology. 2017;233(4):268\u201376.","journal-title":"Dermatology"},{"issue":"4","key":"1931_CR54","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ijd.13591","volume":"56","author":"AS Vacas","year":"2017","unstructured":"Vacas AS, Torre AC, Bollea-Garlatti ML, Warley F, Galimberti RL. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients. Int J Dermatol. 2017;56(4):386\u201391.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1931_CR55","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2165\/00128071-200203030-00002","volume":"3","author":"U Wollina","year":"2002","unstructured":"Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3(3):149\u201358.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1931_CR56","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1002\/art.20559","volume":"50","author":"A Ehling","year":"2004","unstructured":"Ehling A, Karrer S, Klebl F, Sch\u00e4ffler A, M\u00fcller-Ladner U. Therapeutic management of pyoderma gangrenosum. Arthritis Rheum. 2004;50(10):3076\u201384.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1931_CR57","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/bjd.15561","volume":"177","author":"JM Mason","year":"2017","unstructured":"Mason JM, Thomas KS, Ormerod AD, Craig FE, Mitchell E, Norrie J, Williams HCUK. Dermatology Clinical Trials Network\u2019s STOP GAP team. Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. Br J Dermatol. 2017;177(6):1527\u201336.","journal-title":"Br J Dermatol"},{"key":"1931_CR58","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1136\/bmj.h2958","volume":"350","author":"AD Ormerod","year":"2015","unstructured":"Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC. UK Dermatology Clinical Trials Network\u2019s STOP GAP Team. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:2958.","journal-title":"BMJ"},{"issue":"4","key":"1931_CR59","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaad.2013.05.028","volume":"69","author":"J Li","year":"2013","unstructured":"Li J, Kelly R. Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2013;69(4):565\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1931_CR60","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/09546630410020154","volume":"15","author":"MR Lee","year":"2004","unstructured":"Lee MR, Cooper AJ. Mycophenolate mofetil in pyoderma gangrenosum. J Dermatolog Treat. 2004;15(5):303\u20137.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"1931_CR61","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/RHU.0b013e3181f6059f","volume":"16","author":"H Husein-ElAhmed","year":"2010","unstructured":"Husein-ElAhmed H, Callejas-Rubio JL, R\u00edos Fernandez R, Ortego CN. Effectiveness of mycophenolic acid in refractory pyoderma gangrenosum. J Clin Rheumatol. 2010;16(7):346\u20137.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"1931_CR62","first-page":"061","volume":"8","author":"KZ Young","year":"2022","unstructured":"Young KZ, Guan LL, Friedman BJ, Rambhatla PV. Recalcitrant vulvar pyoderma gangrenosum successfully treated with mycophenolate mofetil. Int J Womens Dermatol. 2022;8(3):061.","journal-title":"Int J Womens Dermatol"},{"issue":"2","key":"1931_CR63","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/ajd.13840","volume":"63","author":"A Honigman","year":"2022","unstructured":"Honigman A, Kelly RI. Pyoderma gangrenosum: a review of patient\u2019s demographics, disease and treatment in 118 patients. Austr J Dermatol. 2022;63(2):267\u20139.","journal-title":"Austr J Dermatol"},{"issue":"10","key":"1931_CR64","first-page":"1058","volume":"17","author":"RS Din","year":"2018","unstructured":"Din RS, Tsiaras WG, Li DG, Mostaghimi A. Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review. J Drugs Dermatol. 2018;17(10):1058\u201360.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1931_CR65","first-page":"32","volume":"17","author":"K Herberger","year":"2019","unstructured":"Herberger K, Dissemond J, Br\u00fcggestrat S, Sorbe C, Augustin M. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. J Dtsch Dermatol Ges. 2019;17(1):32\u201341.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"1931_CR66","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1440-0960.2008.00506.x","volume":"50","author":"SE de Zwaan","year":"2009","unstructured":"de Zwaan SE, Iland HJ, Damian DL. Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin. Australas J Dermatol. 2009;50(1):56\u20139.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"1931_CR67","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjd.15850","volume":"178","author":"H Song","year":"2018","unstructured":"Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. Br J Dermatol. 2018;178(2):363\u20138.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1931_CR68","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/09546634.2019.1606888","volume":"31","author":"CK Haag","year":"2020","unstructured":"Haag CK, Ortega-Loayza AG, Latour E, Keller JJ, Fett NM. Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. J Dermatolog Treat. 2020;31(7):723\u20136.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1931_CR69","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/iwj.13067","volume":"16","author":"H Ben Abdallah","year":"2019","unstructured":"Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J. 2019;16(2):511\u201321.","journal-title":"Int Wound J"},{"issue":"3","key":"1931_CR70","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/09546634.2018.1506083","volume":"30","author":"F McKenzie","year":"2019","unstructured":"McKenzie F, Cash D, Gupta A, Cummings LW, Ortega-Loayza AG. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat. 2019;30(3):264\u201376.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1931_CR71","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505\u20139.","journal-title":"Gut"},{"issue":"5","key":"1931_CR72","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/1346-8138.16337","volume":"49","author":"K Yamasaki","year":"2022","unstructured":"Yamasaki K, Yamanaka K, Zhao Y, Iwano S, Takei K, Suzuki K, Yamamoto T. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: final analysis of a 52-week phase 3 open-label study. J Dermatol. 2022;49(5):479\u201387.","journal-title":"J Dermatol"},{"issue":"4","key":"1931_CR73","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1159\/000519320","volume":"238","author":"H Ben Abdallah","year":"2022","unstructured":"Ben Abdallah H, Fogh K, Vestergaard C, Bech R. Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review. Dermatology. 2022;238(4):785\u201392.","journal-title":"Dermatology"},{"issue":"4","key":"1931_CR74","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1080\/09546634.2021.1937475","volume":"33","author":"JS Westerdahl","year":"2022","unstructured":"Westerdahl JS, Nusbaum KB, Chung CG, Kaffenberger BH, Ortega-Loayza AG. Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes. J Dermatolog Treat. 2022;33(4):2386\u201390.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1931_CR75","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/iwj.13359","volume":"17","author":"B Burgdorf","year":"2020","unstructured":"Burgdorf B, Schlott S, Ivanov IH, Dissemond J. Successful treatment of a refractory pyoderma gangrenosum with risankizumab. Int Wound J. 2020;17(4):1086\u20138.","journal-title":"Int Wound J"},{"key":"1931_CR76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jdcr.2021.11.030","volume":"21","author":"AM Reese","year":"2022","unstructured":"Reese AM, Erickson K, Reed KB, Ortega-Loayza AG. Modified dose of guselkumab for treatment of pyoderma gangrenosum. JAAD Case Rep. 2022;21:38\u201342.","journal-title":"JAAD Case Rep"},{"issue":"5","key":"1931_CR77","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/bjd.14037","volume":"173","author":"AG Kolios","year":"2015","unstructured":"Kolios AG, Maul JT, Meier B, Kerl K, Traidl-Hoffmann C, Hertl M, Zillikens D, R\u00f6cken M, Ring J, Facchiano A, Mondino C, Yawalkar N, Contassot E, Navarini AA, French LE. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015;173(5):1216\u201323.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1931_CR78","doi-asserted-by":"publisher","first-page":"542","DOI":"10.23736\/S0392-0488.20.06629-8","volume":"155","author":"G Genovese","year":"2020","unstructured":"Genovese G, Moltrasio C, Garcovich S, Marzano AV. PAPA spectrum disorders. G Ital Dermatol Venereol. 2020;155(5):542\u201350.","journal-title":"G Ital Dermatol Venereol"},{"key":"1931_CR79","first-page":"430","volume":"8","author":"ML McPhie","year":"2020","unstructured":"McPhie ML, Kirchhof MG. Pyoderma gangrenosum treated with secukinumab: a case report. SAGE Open Med Case Rep. 2020;8:430.","journal-title":"SAGE Open Med Case Rep"},{"issue":"11","key":"1931_CR80","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jdcr.2020.08.033","volume":"6","author":"MW Tee","year":"2020","unstructured":"Tee MW, Avarbock AB, Ungar J, Frew JW. Rapid resolution of pyoderma gangrenosum with brodalumab therapy. JAAD Case Rep. 2020;6(11):1167\u20139.","journal-title":"JAAD Case Rep"},{"issue":"9","key":"1931_CR81","doi-asserted-by":"publisher","first-page":"15716","DOI":"10.1111\/dth.15716","volume":"35","author":"AS Kao","year":"2022","unstructured":"Kao AS, King AD, Daveluy S. Successful treatment of cabozantinib-induced pyoderma gangrenosum with ixekizumab therapy: a case report. Dermatol Ther. 2022;35(9):15716.","journal-title":"Dermatol Ther"},{"issue":"10","key":"1931_CR82","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jid.2021.08.046","volume":"141","author":"F Lauffer","year":"2021","unstructured":"Lauffer F, Seiringer P, B\u00f6hmer D, Oesterlin C, Eyerich K. Safety and efficacy of anti-IL-17 (secukinumab) for the treatment of pyoderma gangrenosum. J Investig Dermatol. 2021;141(10):156.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1931_CR83","doi-asserted-by":"publisher","first-page":"13161","DOI":"10.1111\/dth.13161","volume":"33","author":"U Wollina","year":"2020","unstructured":"Wollina U, Sch\u00f6nlebe J, F\u00fcrll C. Pyoderma gangrenosum induced by secukinumab\u2014A late paradoxical drug reaction. Dermatol Ther. 2020;33(1):13161.","journal-title":"Dermatol Ther"},{"key":"1931_CR84","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jdcr.2021.08.021","volume":"16","author":"IR Pollack","year":"2021","unstructured":"Pollack IR, Wolner ZJ, Hammett J, Swerlick RA. Pyoderma gangrenosum in a patient on ixekizumab. JAAD Case Rep. 2021;16:152\u20134.","journal-title":"JAAD Case Rep"},{"issue":"8","key":"1931_CR85","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jdcr.2020.06.011","volume":"6","author":"AJ Petty","year":"2020","unstructured":"Petty AJ, Whitley MJ, Balaban A, Ellington K, Marano AL. Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Rep. 2020;6(8):731\u20133.","journal-title":"JAAD Case Rep"},{"issue":"11","key":"1931_CR86","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/jdv.15714","volume":"33","author":"CD Sadik","year":"2019","unstructured":"Sadik CD, Thieme M, Zillikens D, Terheyden P. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab. J Eur Acad Dermatol Venereol. 2019;33(11):406\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1931_CR87","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjd.18877","volume":"183","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis EJ, Argyropoulou M, Kanni T, Spyridopoulos T, Otto I, Zenker O, Guo R, Riedemann NC. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br J Dermatol. 2020;183(1):176\u20138.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1931_CR88","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1080\/13543784.2020.1819981","volume":"29","author":"JD Lu","year":"2020","unstructured":"Lu JD, Milakovic M, Ortega-Loayza AG, Marzano AV, Alavi A. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. Expert Opin Investig Drugs. 2020;29(11):1179\u201385.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"1931_CR89","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","volume":"17","author":"B Kochar","year":"2019","unstructured":"Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HH. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol. 2019;17(5):991\u20133.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1931_CR90","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/ced.14683","volume":"46","author":"VE Orfaly","year":"2021","unstructured":"Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR. Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol. 2021;46(6):1082\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"1931_CR91","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jdcr.2022.10.001","volume":"30","author":"ZA Bordeaux","year":"2022","unstructured":"Bordeaux ZA, Kwatra SG, West CE. Treatment of pyoderma gangrenosum with apremilast monotherapy. JAAD Case Rep. 2022;30:8\u201310.","journal-title":"JAAD Case Rep"},{"key":"1931_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/jowc.2013.22.Sup1.S1","volume":"22","author":"R Strohal","year":"2013","unstructured":"Strohal R, Dissemond J, Jordan O\u2019Brien J, Piaggesi A, Rimdeika R, Young T, Apelqvist J. An updated overview and clarification of the principle role of debridement. J Wound Care. 2013;22:1\u201352.","journal-title":"J Wound Care"},{"issue":"1","key":"1931_CR93","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000481545","volume":"31","author":"A Kramer","year":"2018","unstructured":"Kramer A, Dissemond J, Kim S, Willy C, Mayer D, Papke R, Tuchmann F, Assadian O. Consensus on wound antisepsis: update 2018. Skin Pharmacol Physiol. 2018;31(1):28\u201358.","journal-title":"Skin Pharmacol Physiol"},{"issue":"2","key":"1931_CR94","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaad.2021.09.053","volume":"86","author":"JL Strunck","year":"2022","unstructured":"Strunck JL, Cutler B, Latour E, Seminario-Vidal L, Ortega-Loayza AG. Wound care dressings for pyoderma gangrenosum. J Am Acad Dermatol. 2022;86(2):458\u201360.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1931_CR95","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jvs.2008.11.049","volume":"49","author":"SK Beidler","year":"2009","unstructured":"Beidler SK, Douillet CD, Berndt DF, Keagy BA, Rich PB, Marston WA. Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. J Vasc Surg. 2009;49(4):1013\u201320.","journal-title":"J Vasc Surg"},{"issue":"9","key":"1931_CR96","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00105-019-4413-9","volume":"70","author":"H Partsch","year":"2019","unstructured":"Partsch H, St\u00fccker M, Vanscheidt W, L\u00e4uchli S, Eder S, Protz K, Dissemond J. Importance of adequate pressure in compression therapy: basis for successful treatment. Hautarzt. 2019;70(9):707\u201314.","journal-title":"Hautarzt"},{"issue":"2","key":"1931_CR97","doi-asserted-by":"publisher","first-page":"14736","DOI":"10.1111\/dth.14736","volume":"34","author":"MM Hobbs","year":"2021","unstructured":"Hobbs MM, Byler R, Latour E, Bonomo L, Hennessy K, Cruz-Diaz CN, Shinohara MM, Seminario-Vidal L, Shinkai K, Ortega-Loayza AG. Treatment of pyoderma gangrenosum: a multicenter survey-based study assessing satisfaction and quality of life. Dermatol Ther. 2021;34(2):14736.","journal-title":"Dermatol Ther"},{"issue":"8","key":"1931_CR98","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/01.ASW.0000755920.76330.21","volume":"34","author":"ML McPhie","year":"2021","unstructured":"McPhie ML, Fletcher J, Machado MO, Carvalho AF, Piguet V, Alavi A. A systematic review of depression and anxiety in adults with pyoderma gangrenosum. Adv Skin Wound Care. 2021;34(8):432\u20136.","journal-title":"Adv Skin Wound Care"},{"issue":"6","key":"1931_CR99","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.jaad.2021.05.040","volume":"86","author":"KB Nusbaum","year":"2022","unstructured":"Nusbaum KB, Ortega-Loayza AG, Kaffenberger BH. Health-related domains of quality of life in pyoderma gangrenosum: a qualitative analysis. J Am Acad Dermatol. 2022;86(6):1382\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1931_CR100","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/bjd\/ljac137","volume":"188","author":"MA Pimentel","year":"2023","unstructured":"Pimentel MA, Li MM, Noe MH, Latour E, Seminario-Vidal L, Greiling T, Shinkai K, Hamilton A, Alavi A, Bolognia JL, Cowen EW, Dominguez A, Fernandez AP, Fivenson D, Huang WW, Madigan LM, Mauskar M, Means AD, Nelson CA, Patsatsi A, Pugliese D, Rojek NW, Rosenbach M, Smith GP, Swerlick RA, Heffernan MP, Mostaghimi A, Ortega-Loayza AG. Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society. Br J Dermatol. 2023;188(4):566\u20138.","journal-title":"Br J Dermatol"},{"key":"1931_CR101","doi-asserted-by":"crossref","unstructured":"Erickson KM, Kody S and Ortega-Loayza AG. Pain as a patient reported outcome measure in pyoderma gangrenosum: defining clinical significance. JAMA Dermatol 2023; accepted for publication","DOI":"10.1001\/jamadermatol.2023.3115"},{"issue":"5","key":"1931_CR102","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/iwj.13389","volume":"17","author":"MM Hobbs","year":"2020","unstructured":"Hobbs MM, Ortega-Loayza AG. Pyoderma gangrenosum: from historical perspectives to emerging investigations. Int Wound J. 2020;17(5):1255\u201365.","journal-title":"Int Wound J"},{"issue":"1","key":"1931_CR103","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1038\/s41598-023-31914-z","volume":"13","author":"RR Moura","year":"2023","unstructured":"Moura RR, Brand\u00e3o L, Moltrasio C, Agrelli A, Tricarico PM, Maronese CA, Crovella S, Marzano AV. Different molecular pathways are disrupted in Pyoderma gangrenosum patients and are associated with the severity of the disease. Sci Rep. 2023;13(1):4919.","journal-title":"Sci Rep"},{"issue":"4","key":"1931_CR104","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/exd.14534","volume":"31","author":"A Flora","year":"2022","unstructured":"Flora A, Kozera E, Frew JW. Pyoderma gangrenosum: a systematic review of the molecular characteristics of disease. Exp Dermatol. 2022;31(4):498\u2013515.","journal-title":"Exp Dermatol"},{"issue":"6","key":"1931_CR105","first-page":"8805","volume":"12","author":"S Alkeraye","year":"2020","unstructured":"Alkeraye S, AlZamil LR, Alenazi S. Dapsone in the management of pemphigus and pemphigoid: rediscovery of its long-lost efficacy. Cureus. 2020;12(6):8805.","journal-title":"Cureus"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01931-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01931-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01931-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T16:11:20Z","timestamp":1703002280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01931-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":105,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1931"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01931-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"1 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dissemond received educational and research funding and\/or contributed to advisory work for Infectopharm, InflaRx, Jansen Cilag and Novartis. Marzano received educational and research funding and\/or contributed to advisory work for Abbvie, Boehringer-Ingelheim, Novartis, Pfizer, Sanofi and UCB. Hampton received educational and research funding and\/or contributed to advisory work for Abbvie, Almiral, UCB, Jansen and Novartis. Ortega Loayza received educational and research funding and\/or contributed to advisory work for Genentech, Guidepoint, Bristol Meyer Squibb, Boehringer Ingelheim, Janssen, Lilly, Janssen and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JD: Planning, writing several sections, revision of the whole manuscript. AVN: Writing one section, revision of the whole manuscript. PJH: Writing one section, revision of the whole manuscript. AGOL: Planning, writing several sections, revision of the whole manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}